Introduction: Patients who had lobectomy prior to thoracic radiotherapy may be more prone to developing radiation pneumonitis (RP) given their smaller remaining lung volume. There is no consensus on the normal lung dose constraints in this population. V20 ≤30% to 35% and mean lung dose (MLD) ≤20 Gy are common dose constraints used in definitive radiotherapy for lung cancer. We aimed to determine whether V20 ≤33% and mean MLD ≤20 Gy are safe constraints with an acceptable risk of RP in post-lobectomy patients. Methods: The data of all patients who received post-lobectomy thoracic radiotherapy for non-small-cell lung cancer at a single centre in Hong Kong from 2011 to 2018 were analysed retrospectively. The endpoint was Common Terminology Criteria for Adverse Events (CTCAE) grade ≥3 RP. Statistical analysis was performed to investigate whether V10 and V20 of whole lung were predictive factors for RP. Results: Fifty-five patients had been treated using the dose constraints of V20 ≤33% and MLD ≤20 Gy. Three patients developed grade 5 RP. No patients had grade 3 or 4 RP. There was no significant association between the V10, V20 and grade ≥3 RP. Conclusion: Our data showed that the risk of grade ≥3 RP was 5.5% in post-lobectomy patients using dose constraints of V20 ≤33% and MLD ≤20 Gy. Further prospective studies are necessary to clarify the optimal dose constraints in this population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.